Cardium (CXM) Plans File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL
More News related to CXM
- Cardium Reports on Third Quarter 2009 Financial Results and Recent Developments
- Cardium (CXM) Plans File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL
- Cardium Announces Plans to File FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Gel for Diabetic, Pressure and Venous Ulcers and Other Topical Wounds
- Cardium Completes $6.0 Million Registered Direct Offering
- Trading Review for Cardium Therapeutics Inc. Issued by Beacon Equity
More News related to FDA
- Transcept Pharma (TSPT) to Meet with U.S. FDA To Discuss NDA Response Letter for Intermezzo
- DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
- Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
- ARCA Biopharma (ABIO) Annouces Gencaro OK'd by U.S. FDA for Fast Track Program
- Ception and Cephalon (CEPH) Report Initial Results from Phase IIb/III Trial for CINQUIL(TM)
Cardium Therapeutics (Amex: CXM) plans to submit a 510(k) premarket notification with the FDA seeking marketing clearance of its ExcellagenXL product candidate.
ExcellagenXL is an advanced wound care management medical device, which is a customized collagen-based topical gel designed for use by physicians in patients with topical wounds, which include diabetic ulcers as well as pressure ulcers, venous ulcers, surgical and trauma wounds, second degree burns, and other types of wounds. The Company expects to submit its FDA 510(k) application for ExcellagenXL during the current quarter.
Related Categories
FDAStocks Mentioned
-0.02Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
